Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KOD Kodiak Sciences Inc.

Trading 09-08 12:59:19 EDT

34.66

-0.70

-1.99%

High35.11	Low33.92	Vol216.47K
Open34.71	D1 Closing35.36	Amplitude3.35%
Mkt Cap2.17B	Tradable Cap1.40B	Total Shares62.58M
T/O7.48M	T/O Rate0.54%	Tradable Shares40.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KOD","market":"US","secType":"STK","nameCN":"Kodiak Sciences Inc.","latestPrice":34.655,"timestamp":1788886748338,"preClose":35.36,"halted":0,"volume":216468,"delay":0,"changeRate":-0.019937782805429818,"floatShares":40285901,"shares":62578441,"eps":-4.157111,"marketStatus":"Trading","change":-0.705,"latestTime":"09-08 12:59:19 EDT","open":34.71,"high":35.105,"low":33.92,"amount":7480377.091404,"amplitude":0.033512,"askPrice":34.67,"askSize":24,"bidPrice":34.6,"bidSize":208,"shortable":3,"etf":0,"ttmEps":-4.157111,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788897600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":35.36,"preHourTrading":{"tag":"盘前","latestPrice":34.5655,"preClose":35.36,"latestTime":"09:28 EDT","volume":2510,"amount":87545.20317,"timestamp":1788874080122,"change":-0.7945,"changeRate":-0.022469,"amplitude":0.113122},"postHourTrading":{"tag":"盘后","latestPrice":35.01,"preClose":35.36,"latestTime":"19:51 EDT","volume":33803,"amount":1193223.362,"timestamp":1788565873519,"change":-0.35,"changeRate":-0.009898,"amplitude":0.018382},"volumeRatio":0.630735,"impliedVol":1.8672,"impliedVolPercentile":0.9801},"requestUrl":"/m/hq/s/KOD","defaultTab":"news","newsList":[{"id":"2663704542","title":"KPK Seizes Rp6 Billion in Silmy Karim Foreign Residence Permit Extortion Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2663704542","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663704542?lang=en_us&edition=fundamental","pubTime":"2026-08-30 10:27","pubTimestamp":1788056851,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta-Investigators from the Indonesian Corruption Eradication Commission  seized Rp6 billion during the investigation into alleged extortion related to the processing of foreign nationals' residence permits—a case implicating the former Deputy Minister of Immigration and Correctional Affairs, Silmy Karim. The funds were seized while investigators were questioning three witnesses on Friday, August 28, 2026.KPK spokesperson Budi Prasetyo stated that the money is suspected to be proceeds from the extortion of foreign nationals applying for residence permits at the Directorate General of Immigration under the Ministry of Immigration and Correctional Affairs. \"Investigators examined the witnesses' statements regarding the procedures for foreign national residence permit services,\" Budi said when asked for confirmation by Tempo on Saturday, August 29, 2026.Budi noted that investigators questioned each witness regarding the alleged receipt of funds. The KPK suspects that several ","market":"other","thumbnail":"https://statik.tempo.co/data/2026/06/08/id_1476804/1476804_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/06/08/id_1476804/1476804_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2118547/kpk-seizes-rp6-billion-in-silmy-karim-foreign-residence-permit-extortion-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2118547/kpk-seizes-rp6-billion-in-silmy-karim-foreign-residence-permit-extortion-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK4139","LU2106854487.HKD","ALB","BK4109","BK4585","LU1244550577.SGD","LU1803068623.USD","LU0823414551.USD","IDRV","LU1720051108.HKD","LIT","ALB.AU","LU1244550221.USD","BK4588","LU2360107325.USD","LU2506951792.HKD","LIMI","LU2023250504.SGD","LU2357305700.SGD","ALBG","KOD","BK4505","SETM","ILIT","LU2048586759.USD","LU2294711713.HKD","LU1720051017.SGD","LITP","LU1974910355.USD","RHS","BK4545","LU1861214812.USD","LU1861219969.SGD","LU1548497426.USD","LU2357125470.USD","BK7095","REMX","LU1244550494.USD","LU1878469433.USD","LU1917777945.USD","LU2249611893.SGD","LU0823414478.USD","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661329487","title":"Kodiak Sciences Advances ALTO Phase 3 Trial In Diabetic Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2661329487","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661329487?lang=en_us&edition=fundamental","pubTime":"2026-08-22 00:32","pubTimestamp":1787329930,"startTime":"0","endTime":"0","summary":"Kodiak Sciences ($KOD) announced an update on their ongoing clinical study. Kodiak Sciences Inc. (KOD) is running a Phase 3 study called ALTO to co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kodiak-sciences-advances-alto-phase-3-trial-in-diabetic-eye-disease?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kodiak-sciences-advances-alto-phase-3-trial-in-diabetic-eye-disease?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4505","ALTO","KOD","BK4109","BK4138"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660482433","title":"Kodiak Sciences Price Target Maintained with a $58.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2660482433","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660482433?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:57","pubTimestamp":1786967820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KOD/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659173451","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2659173451","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659173451?lang=en_us&edition=fundamental","pubTime":"2026-08-15 22:30","pubTimestamp":1786804224,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kodiak Sciences (KOD) and Oruka Therapeutics (ORKA) ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-303?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-303?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KOD","LU0109394709.USD","ORKA","BK4139","BK4505","LU0889565916.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659413145","title":"Outlook Therapeutics Q3 Net Loss Narrows Slightly as Costs Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2659413145","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659413145?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:26","pubTimestamp":1786706773,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Q3 net loss narrows slightly as costs dropOverviewU.S. biopharmaceutical firm's fiscal Q3 net loss narrowedCompany advancing U.S. launch strategy for LYTENAVA, FDA-approved ophtha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","PLRX","OTLK","BK4505","BK4139","LENZ","KOD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659193899","title":"Heart Drug Developer Atrium Therapeutics' Q2 Loss Widens as Expenses Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2659193899","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659193899?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:46","pubTimestamp":1786657566,"startTime":"0","endTime":"0","summary":"Heart drug developer Atrium Therapeutics' Q2 loss widens as expenses riseOverviewU.S. biopharmaceutical firm's Q2 collaboration revenue fell yr/yr as R&D services declinedCompany posted wider net loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A1BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1032466523.USD","IE0002141913.USD","LU0868494617.USD","LU1323610961.USD","BMY","LU0432979614.USD","LU1571399168.USD","LU2596442595.SGD","IE00BJT1NW94.SGD","LU1430594728.SGD","LU1670710588.SGD","LU1868836591.USD","BK4007","LU0985481810.HKD","LU1883839398.USD","BK4505","LU1989771016.USD","LU2242652126.USD","LU1718418525.SGD","IE00BSNM7G36.USD","LU1983299246.USD","LU1093756168.USD","IE00BJJMRZ35.SGD","IE0009354923.USD","LU1670710661.SGD","LU0306806265.USD","BK4559","BK4532","LU1093756325.SGD","LU1868836757.USD","LU1868836914.USD","LU0225284248.USD","LU2125154778.USD","LU0456855351.SGD","LU1291159041.SGD","ENSC","BK4585","LU0237698245.USD","RNA","BK4588","IE00B2B36J28.USD","FTXH","IHE","IE00BFXG1179.USD","LU1074936037.SGD","LU1868837300.USD","BK4139","BK4534","KOD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167963","title":"Ensysce Biosciences Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167963","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167963?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:25","pubTimestamp":1786652704,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences Q2 net loss widens on higher R&D costsOverviewUS biotech firm's Q2 net loss widened yr/yr on higher R&D expensesCompany completed Cy Biopharma acquisition post-quarter, adding CY20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD","BK4139","BK4505","APRE","ENSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162270","title":"Kodiak Sciences Q2 Net Income USD -65.643 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162270","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162270?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:13","pubTimestamp":1786652021,"startTime":"0","endTime":"0","summary":"Aug 13 (Reuters) - Kodiak Sciences Q2 basic EPS USD -1.05.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 13-AUG-202619:45:32.103 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nRSD6tvlsj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659616245","title":"Kodiak Sciences Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659616245","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659616245?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:10","pubTimestamp":1786651846,"startTime":"0","endTime":"0","summary":"Kodiak Sciences Inc. reports results for the quarter ended June 30 - Earnings SummaryKodiak Sciences Inc.KOD.OQreported a quarterly adjusted loss of $1.05 per share for the quarter ended June 30, lowe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A240:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162883","title":"Kodiak Sciences Q2 EPS $(1.05) Misses $(0.95) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162883","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162883?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:03","pubTimestamp":1786651405,"startTime":"0","endTime":"0","summary":"Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.95) by 10.53 percent. This is a 1.94 percent decrease over losses of $(1.03) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61191816/kodiak-sciences-q2-eps-1-05-misses-0-95-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kodiak Sciences Q2 EPS $(1.05) Misses $(0.95) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659752164","title":"Kodiak Sciences Q2 FY26 Net Loss Widens to $65.64 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659752164","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659752164?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:00","pubTimestamp":1786651240,"startTime":"0","endTime":"0","summary":"Kodiak Sciences Q2 FY26 net loss widens to $65.64 millionKodiak Sciences posted a GAAP net loss of USD 65.6 million, or USD 1.05 a share, for the second quarter ended June 30, 2026.R&D expense climbed","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLccFWKS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659164200","title":"Kodiak Sciences Q2 Operating Income USD -66.838 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659164200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659164200?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:00","pubTimestamp":1786651201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLX0P4WLX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658527339","title":"Kodiak Sciences Says First Patients Enrolled in Late-Stage Diabetic Eye Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2658527339","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658527339?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:49","pubTimestamp":1786398571,"startTime":"0","endTime":"0","summary":"Kodiak Sciences  said late Monday that the first patients have been enrolled in the phase 3 trial evaluating the safety and efficacy of the KSI-501 candidate to treat diabetic macular edema.The primary endpoint of the trial is the mean change in best-corrected visual acuity from baseline to the average of week 48 and week 52, while the key secondary endpoint is the proportion of patients improving two or more steps on the Diabetic Retinopathy Severity Scale from baseline at week 48, the company said.The company estimates that 910 patients will partake in the randomized trial, according to a statement.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","KOD","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658495172","title":"Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 Alto Trial of Ksi-501 in Patients with Diabetic Macular Edema","url":"https://stock-news.laohu8.com/highlight/detail?id=2658495172","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658495172?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:43","pubTimestamp":1786394633,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUAC4TGRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KOD","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658147672","title":"Kodiak Sciences (KOD) Is Up 9.1% After Advancing KSI-101 Phase 3 PEAK Trial Enrollment – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658147672","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658147672?lang=en_us&edition=fundamental","pubTime":"2026-08-09 16:36","pubTimestamp":1786264567,"startTime":"0","endTime":"0","summary":"Kodiak Sciences has completed enrollment of the first 300-patient cohort in its Phase 3 PEAK trial of KSI-101 for macular edema secondary to inflammation, advancing a bispecific IL-6/VEGF therapy through a pivotal analysis that will inform regulatory paths.\nAn interesting aspect of this update is how PEAK and the complementary PINNACLE study are structured to span a broad spectrum of MESI severity, from mild to more advanced disease, potentially broadening the therapy’s clinical relevance if...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/kodiak-sciences-kod-is-up-91-after-advancing-ksi-101-phase-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/kodiak-sciences-kod-is-up-91-after-advancing-ksi-101-phase-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","KSI","BK4139","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657617666","title":"Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), Kodiak Sciences (KOD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657617666","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657617666?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:30","pubTimestamp":1786051816,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Climb Bio (CLYM), Kodiak Sciences (KOD) and Viridian...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-climb-bio-clym-kodiak-sciences-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-climb-bio-clym-kodiak-sciences-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM","BK4505","BK4539","KOD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680219","title":"Kodiak Sciences - Completes Enrollment in First Phase 3 Peak Cohort; Topline Data Expected December 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680219","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680219?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUACCQVCH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652268757","title":"Berenberg Bank Remains a Buy on Kodal Minerals (KOD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2652268757","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652268757?lang=en_us&edition=fundamental","pubTime":"2026-07-20 07:35","pubTimestamp":1784504145,"startTime":"0","endTime":"0","summary":"Berenberg Bank analyst Will Dalby reiterated a Buy rating on Kodal Minerals on July 17 and set a price target of p1.00. The company’s shares closed...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/berenberg-bank-remains-a-buy-on-kodal-minerals-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/berenberg-bank-remains-a-buy-on-kodal-minerals-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4109","KOD","BK4139","BK4505","MTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648796696","title":"Is Kodiak Sciences’ (KOD) Shift Into Russell Growth Indices Reframing Its Core Investment Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2648796696","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648796696?lang=en_us&edition=fundamental","pubTime":"2026-07-04 15:20","pubTimestamp":1783149654,"startTime":"0","endTime":"0","summary":"On 27 June 2026, Kodiak Sciences Inc. was removed from several Russell value and microcap benchmarks while being added to multiple Russell growth indices, including the Russell 2000 Growth and Russell 3000 Growth benchmarks.\nThis broad shift from value and microcap classifications to growth-focused indices signals a meaningful change in how Kodiak Sciences is categorized by major index providers.\nNext, we’ll examine how this reclassification into growth-oriented Russell benchmarks influences...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/is-kodiak-sciences-kod-shift-into-russell-growth-indices-ref","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/is-kodiak-sciences-kod-shift-into-russell-growth-indices-ref","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","BK4139","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641128453","title":"Kodiak Sciences CFO John A. Borgeson disposes of common shares worth $1.02 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2641128453","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641128453?lang=en_us&edition=fundamental","pubTime":"2026-06-06 05:57","pubTimestamp":1780696654,"startTime":"0","endTime":"0","summary":"Kodiak Sciences CFO John A. Borgeson sold 30,000 common shares on June 4, 2026, cutting his stake to 211,930 shares.The sales were priced at USD 34.01 for 25,896 shares, USD 34.67 for 4,104 shares.Borgeson also exercised a stock option for 30,000 shares at USD 1.04 on the same day.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDLcdYQDw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kodiak Sciences CFO John A. Borgeson disposes of common shares worth $1.02 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KOD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kodiak.com;ir.kodiak.com","stockEarnings":[{"period":"1week","weight":-0.0626},{"period":"1month","weight":-0.1892},{"period":"3month","weight":0.1388},{"period":"6month","weight":0.4224},{"period":"1year","weight":3.1357},{"period":"ytd","weight":0.2647}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.076525},{"month":2,"riseRate":0.5,"avgChangeRate":-0.093763},{"month":3,"riseRate":0.125,"avgChangeRate":-0.076889},{"month":4,"riseRate":0.625,"avgChangeRate":0.017136},{"month":5,"riseRate":0.5,"avgChangeRate":0.047406},{"month":6,"riseRate":0.75,"avgChangeRate":0.031274},{"month":7,"riseRate":0.625,"avgChangeRate":0.076709},{"month":8,"riseRate":0.5,"avgChangeRate":0.003695},{"month":9,"riseRate":0.625,"avgChangeRate":0.105134},{"month":10,"riseRate":0.714286,"avgChangeRate":0.212883},{"month":11,"riseRate":0.75,"avgChangeRate":0.296496},{"month":12,"riseRate":0.625,"avgChangeRate":0.266402}],"exchange":"NASDAQ","name":"Kodiak Sciences Inc.","nameEN":"Kodiak Sciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kodiak Sciences Inc.(KOD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kodiak Sciences Inc.,KOD,Kodiak Sciences Inc.股票,Kodiak Sciences Inc.股票老虎,Kodiak Sciences Inc.股票老虎国际,Kodiak Sciences Inc.行情,Kodiak Sciences Inc.股票行情,Kodiak Sciences Inc.股价,Kodiak Sciences Inc.股市,Kodiak Sciences Inc.股票价格,Kodiak Sciences Inc.股票交易,Kodiak Sciences Inc.股票购买,Kodiak Sciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kodiak Sciences Inc.(KOD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction